Amidate is a small molecule that works as a GABA-a Receptor; Anion Channel Positive Modulator.[2] It is being used across 16 indications, with its most advanced program in Approved.[1]
Amidate is one of 393 small molecule programs targeting Respiratory Failure. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
198 competitors in Heart Failure
Amidate
Bayer Aspirin
Brethine
Medrol
Activase
Zemplar
Adriamycin
Savaysa
Xylocaine
Tamiflu
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Sep 7, 1982
AMIDATE
NDA NDA018227
May 30, 1985
AMIDATE
NDA NDA018227
May 30, 1985
AMIDATE
NDA NDA018227
Feb 15, 1986
AMIDATE
NDA NDA018227
Jun 16, 1986
AMIDATE
NDA NDA018227
Jan 25, 1988
AMIDATE
NDA NDA018227
Jul 1, 1994
AMIDATE
NDA NDA018227
Sep 11, 1996
AMIDATE
NDA NDA018227
Apr 30, 1997
AMIDATE
NDA NDA018227
Sep 29, 1998
AMIDATE
NDA NDA018227
Feb 26, 1999
AMIDATE
NDA NDA018227
Apr 29, 1999
AMIDATE
NDA NDA018227
Apr 6, 2001
AMIDATE
NDA NDA018227
Jul 3, 2002
AMIDATE
NDA NDA018227
Jul 3, 2002
AMIDATE
NDA NDA018227
Apr 27, 2017
AMIDATE
NDA NDA018227
Sources